| Patient | Irène Joliot-Curie |
|---|---|
| Date of birth | 1897-09-12 |
| Identifiers | MRN HR-RB003-SYN-TD; SSN (made up) 000-03-8841 |
| Document date | 2026-11-01 |
| Author | Solène Marchand-Ellis, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient visit for two months of tiredness, bruising and bleeding gums: blood count with blasts on the smear, and urgent hematology referral. Concerns: She has been worn out for two months, bruises easily and her gums bleed; she suspects her blood and wants to know at once; She knows the long-term effects of radiation on the bone marrow from her own field and from her mother's illness, and wants her exposure history taken seriously. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Azacitidine 115 mg (75 mg/m2) under the skin once daily on days 1 to 7 of each 28-day cycle | Once daily on days 1 to 7 of each 28-day cycle | Subcutaneous route | 1955-09-28 | active | S |
| Venetoclax 10 mg oral tablet, cycle 1: 10 mg on day 1 and 20 mg on day 2, then two tablets (20 mg) daily with the 50 mg tablet from day 4 (70 mg a day, reduced for posaconazole) | Ramp-up, then two tablets daily with the 50 mg tablet, with food and water | Oral route | 1955-09-28 to 1955-10-19 | completed | S |
| Venetoclax 50 mg oral tablet, cycle 1: one tablet alone on day 3 (50 mg), then one tablet daily with two 10 mg tablets from day 4 (70 mg a day) | One tablet daily from day 3, with food and water | Oral route | 1955-09-28 to 1955-10-19 | completed | S |
| Posaconazole 100 mg delayed-release tablet, three tablets (300 mg) twice on day 1, then three tablets once daily, as antifungal prophylaxis while neutropenic | 300 mg twice on day 1, then 300 mg once daily with food | Oral route | 1955-09-28 | active | S |
| Acyclovir 400 mg oral tablet, one tablet twice daily as herpes simplex and zoster prophylaxis | One tablet twice daily | Oral route | 1955-09-28 | active | S |
| Levofloxacin 500 mg oral tablet, one tablet daily while the neutrophil count is below 0.5 | One tablet daily during profound neutropenia | Oral route | 1955-09-28 to 1955-10-30 | completed | S |
| Allopurinol 300 mg oral tablet, one tablet daily for tumor lysis prophylaxis during cycle 1 | One tablet daily | Oral route | 1955-09-28 to 1955-10-19 | completed | S |
| Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for nausea | One tablet every 8 hours as needed | Oral route | 1955-10-08 | active | S |
| Polyethylene glycol 3350, 17 g powder in a glass of water once daily | 17 g once daily, held for loose stools | Oral route | 1955-10-08 | active | S |
| Sennosides 8.6 mg oral tablet, two tablets at bedtime | Two tablets at bedtime | Oral route | 1955-10-08 to 1955-10-19 | completed | S |
| Potassium chloride 20 mEq extended-release tablet, one tablet twice daily for three days | One tablet twice daily for three days | Oral route | 1955-10-08 to 1955-10-11 | completed | S |
| Venetoclax 10 mg oral tablet, cycle 2: two tablets daily with the 50 mg tablet (70 mg a day, the dose with posaconazole) on days 1 to 21 | Two tablets daily on days 1 to 21, with food and water | Oral route | 1955-10-30 | active | S |
| Venetoclax 50 mg oral tablet, cycle 2: one tablet daily with two 10 mg tablets (70 mg a day) on days 1 to 21 | One tablet daily on days 1 to 21, with food and water | Oral route | 1955-10-30 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Bone marrow aspiration and trephine biopsy, posterior iliac crest, with flow cytometry, cytogenetics and molecular testing | 1955-09-16 to 1955-09-16 | completed | S |
| Transfusion of one unit of irradiated, leukoreduced red cells for symptomatic anemia (hemoglobin 7.1 g/dL) | 1955-09-16 to 1955-09-16 | completed | S |
| Chest X-ray, posteroanterior and lateral | 1955-09-16 to 1955-09-16 | completed | S |
| Pulmonary function tests with diffusing capacity | 1955-09-28 to 1955-09-28 | completed | S |
| Transthoracic echocardiogram | 1955-09-28 to 1955-09-28 | completed | S |
| Twelve-lead ECG before posaconazole | 1955-09-28 to 1955-09-28 | completed | S |
| Bone marrow aspiration and biopsy on day 22 of cycle 1, with flow cytometry for measurable residual disease | 1955-10-19 to 1955-10-19 | completed | S |
| Transfusion of one unit of irradiated, leukoreduced red cells (hemoglobin 7.4 g/dL with tiredness) | 1955-10-08 to 1955-10-08 | completed | S |
| Transfusion of one dose of irradiated platelets (count 9 x10^3/uL) | 1955-10-08 to 1955-10-08 | completed | S |
| Twelve-lead ECG before an antiemetic | 1955-10-08 to 1955-10-08 | completed | S |
| Advance care planning conversation, about 30 minutes | 1955-10-26 to 1955-10-26 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1955-10-26 | Influenza vaccine, inactivated, this season | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1914 | Worked as a nurse radiographer with X-ray machines in field hospitals in the First World War, the start of her occupational radiation exposure | D (CLM-0002) |
| 1944 | Tuberculosis, with a long recovery in Switzerland during the Second World War | D (CLM-0008) |
| 1946 | A capsule of polonium exploded on her laboratory bench | D (CLM-0010) |
| 1950 | Health visibly declining from shortly after this year | D (CLM-0013) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| mother | A physicist who also worked with radioactive materials; died of aplastic anemia that her physician attributed to bone marrow injury from long exposure to radiation | D (CLM-0016) |
| Concern | Status | Evidence |
|---|---|---|
| She has been worn out for two months, bruises easily and her gums bleed; she suspects her blood and wants to know at once | active | S |
| She knows the long-term effects of radiation on the bone marrow from her own field and from her mother's illness, and wants her exposure history taken seriously | active | S |
Most recent measures: Leukocytes [#/volume] in Blood by Automated count 0.7 on 1955-10-08; Neutrophils [#/volume] in Blood by Automated count 0.1 on 1955-10-08; Hemoglobin [Mass/volume] in Blood 7.4 on 1955-10-08; MCV [Entitic mean volume] in Red Blood Cells by Automated count 104 on 1955-09-14; Platelets [#/volume] in Blood by Automated count 9 on 1955-10-08; Blasts/Leukocytes in Blood by Manual count 0 on 1955-10-30; Sodium [Moles/volume] in Serum or Plasma 137 on 1955-10-08; Potassium [Moles/volume] in Serum or Plasma 3.3 on 1955-10-08; Creatinine [Mass/volume] in Serum or Plasma 0.84 on 1955-10-08; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1950)/1.73 sq M 84 on 1955-10-30; Calcium [Mass/volume] in Serum or Plasma 9.1 on 1955-09-28; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 28 on 1955-10-30; Bilirubin.total [Mass/volume] in Serum or Plasma 0.7 on 1955-09-28; Albumin [Mass/volume] in Serum or Plasma 3.9 on 1955-09-14; Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma 196 on 1955-10-19; Urate [Mass/volume] in Serum or Plasma 5.8 on 1955-09-28; ECOG Performance Status score 1 on 1955-10-30; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 on 1955-10-30; Blasts/cells in Bone marrow 3 on 1955-10-19; INR in Platelet poor plasma by Coagulation assay 1.1 on 1955-09-16; Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay 310 on 1955-09-16; Phosphate [Mass/volume] in Serum or Plasma 3.6 on 1955-09-28; Diffusion capacity.carbon monoxide/Predicted 58 on 1955-09-28; FEV1 measured/predicted 76 on 1955-09-28; Left ventricular Ejection fraction 62 on 1955-09-28; Q-T interval corrected 446 on 1955-10-08; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 5 on 1955-10-26; Magnesium [Mass/volume] in Serum or Plasma 1.8 on 1955-10-08; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 1955-10-26; Total score [AUDIT-C] 1 on 1955-10-26 [S]
Strengths and supports: Supports: a close family, long-standing colleagues, and work she believes in [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Two months of tiredness, easy bruising and bleeding gums, with pancytopenia and 12 percent blasts on the blood smear; acute leukemia suspected and urgent hematology review booked | resolved | confirmed | D61.818 | S — Synthetic presenting concern at the index visit, superseded by the bone marrow diagnosis two days later; its timing echoes the documented decline in her health (D). |
| Acute myeloid leukemia diagnosed on bone marrow biopsy (34 percent myeloblasts), in a physicist with decades of occupational exposure to ionizing radiation; synthetic modern diagnosis linked to her documented leukemia | active | confirmed | C92.00 | S — Synthetic modern diagnosis and subtype; the type of her real leukemia is not documented. |
| Occupational exposure to ionizing radiation over about four decades: X-ray work early in her career, laboratory work with polonium and other radioactive sources, and a laboratory accident in which a sealed polonium source ruptured on her bench about ten years ago | active | confirmed | Z57.1 | S — Synthetic modern coding of her documented occupational exposure. |
| Pulmonary tuberculosis in her forties, treated to completion; no symptoms of active disease | active | confirmed | Z86.11 | S — Synthetic modern coding of her documented tuberculosis; the treatment details are synthetic. |
| Moderately reduced lung gas transfer (DLCO 58 percent of predicted, FEV1 76 percent) from old tuberculous scarring of the right upper lobe; with performance status 2, it makes her unfit for intensive induction | active | confirmed | R94.2 | S — Synthetic finding on pre-treatment testing. |
| Nausea with vomiting and constipation on day 11 of cycle 1 of azacitidine with venetoclax, without fever, with mild low potassium; managed as an outpatient; resolved | resolved | confirmed | R11.2 | S — Synthetic treatment side effect; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1955-09-14 | Leukocytes [#/volume] in Blood by Automated count | 2.1 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 1955-09-14 | Neutrophils [#/volume] in Blood by Automated count | 0.6 | 10*3/uL | 1.5-7.5 10*3/uL | Low | S |
| 1955-09-14 | Hemoglobin [Mass/volume] in Blood | 8.4 | g/dL | 12-15.5 g/dL | Low | S |
| 1955-09-14 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 104 | fL | 80-100 fL | High | S |
| 1955-09-14 | Platelets [#/volume] in Blood by Automated count | 38 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 1955-09-14 | Blasts/Leukocytes in Blood by Manual count | 12 | % | None seen normally | High | S |
| 1955-09-14 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1955-09-14 | Potassium [Moles/volume] in Serum or Plasma | 4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1955-09-14 | Creatinine [Mass/volume] in Serum or Plasma | 0.78 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 1955-09-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1950)/1.73 sq M | 88 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1955-09-14 | Calcium [Mass/volume] in Serum or Plasma | 9.2 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1955-09-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-35 U/L | Normal | S |
| 1955-09-14 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1955-09-14 | Albumin [Mass/volume] in Serum or Plasma | 3.9 | g/dL | 3.5-5 g/dL | Normal | S |
| 1955-09-14 | Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma | 412 | U/L | 140-280 U/L | High | S |
| 1955-09-14 | Urate [Mass/volume] in Serum or Plasma | 6.4 | mg/dL | 2.6-6 mg/dL | High | S |
| 1955-09-14 | ECOG Performance Status score | 1 | {score} | S | ||
| 1955-09-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 1955-09-16 | Leukocytes [#/volume] in Blood by Automated count | 1.9 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 1955-09-16 | Neutrophils [#/volume] in Blood by Automated count | 0.5 | 10*3/uL | 1.5-7.5 10*3/uL | Low | S |
| 1955-09-16 | Hemoglobin [Mass/volume] in Blood | 7.1 | g/dL | 12-15.5 g/dL | Low | S |
| 1955-09-16 | Platelets [#/volume] in Blood by Automated count | 22 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 1955-09-16 | Blasts/Leukocytes in Blood by Manual count | 14 | % | None seen normally | High | S |
| 1955-09-16 | Blasts/cells in Bone marrow | 34 | % | Below 5% normally; 20% or more defines AML | High | S |
| 1955-09-16 | INR in Platelet poor plasma by Coagulation assay | 1.1 | {INR} | 0.8-1.2 | Normal | S |
| 1955-09-16 | Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay | 310 | mg/dL | 200-400 mg/dL | Normal | S |
| 1955-09-28 | Leukocytes [#/volume] in Blood by Automated count | 1.6 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 1955-09-28 | Neutrophils [#/volume] in Blood by Automated count | 0.4 | 10*3/uL | 1.5-7.5 10*3/uL | Low | S |
| 1955-09-28 | Hemoglobin [Mass/volume] in Blood | 8.6 | g/dL | 12-15.5 g/dL | Low | S |
| 1955-09-28 | Platelets [#/volume] in Blood by Automated count | 18 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 1955-09-28 | Blasts/Leukocytes in Blood by Manual count | 16 | % | None seen normally | High | S |
| 1955-09-28 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1955-09-28 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1955-09-28 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 1955-09-28 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1950)/1.73 sq M | 85 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1955-09-28 | Calcium [Mass/volume] in Serum or Plasma | 9.1 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1955-09-28 | Phosphate [Mass/volume] in Serum or Plasma | 3.6 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 1955-09-28 | Urate [Mass/volume] in Serum or Plasma | 5.8 | mg/dL | 2.6-6 mg/dL | Normal | S |
| 1955-09-28 | Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma | 448 | U/L | 140-280 U/L | High | S |
| 1955-09-28 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-35 U/L | Normal | S |
| 1955-09-28 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1955-09-28 | Diffusion capacity.carbon monoxide/Predicted | 58 | % | 80% of predicted or more | Low | S |
| 1955-09-28 | FEV1 measured/predicted | 76 | % | >=80% | Low | S |
| 1955-09-28 | Left ventricular Ejection fraction | 62 | % | 55-70% | Normal | S |
| 1955-09-28 | Q-T interval corrected | 428 | ms | Above 460 ms is prolonged in women | Normal | S |
| 1955-09-28 | ECOG Performance Status score | 2 | {score} | S | ||
| 1955-09-28 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 1955-09-28 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | {score} | S | ||
| 1955-10-19 | Leukocytes [#/volume] in Blood by Automated count | 0.6 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 1955-10-19 | Neutrophils [#/volume] in Blood by Automated count | 0.2 | 10*3/uL | 1.5-7.5 10*3/uL | Low | S |
| 1955-10-19 | Hemoglobin [Mass/volume] in Blood | 8.9 | g/dL | 12-15.5 g/dL | Low | S |
| 1955-10-19 | Platelets [#/volume] in Blood by Automated count | 31 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 1955-10-19 | Blasts/Leukocytes in Blood by Manual count | 0 | % | None seen normally | Normal | S |
| 1955-10-19 | Blasts/cells in Bone marrow | 3 | % | Below 5% normally; 20% or more defines AML | Normal | S |
| 1955-10-19 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 1955-10-19 | Potassium [Moles/volume] in Serum or Plasma | 3.9 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1955-10-19 | Creatinine [Mass/volume] in Serum or Plasma | 0.79 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 1955-10-19 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1950)/1.73 sq M | 87 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1955-10-19 | Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma | 196 | U/L | 140-280 U/L | Normal | S |
| 1955-10-19 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-35 U/L | Normal | S |
| 1955-10-30 | Leukocytes [#/volume] in Blood by Automated count | 2.2 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 1955-10-30 | Neutrophils [#/volume] in Blood by Automated count | 0.9 | 10*3/uL | 1.5-7.5 10*3/uL | Low | S |
| 1955-10-30 | Hemoglobin [Mass/volume] in Blood | 9.6 | g/dL | 12-15.5 g/dL | Low | S |
| 1955-10-30 | Platelets [#/volume] in Blood by Automated count | 88 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 1955-10-30 | Blasts/Leukocytes in Blood by Manual count | 0 | % | None seen normally | Normal | S |
| 1955-10-30 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1955-10-30 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1955-10-30 | Creatinine [Mass/volume] in Serum or Plasma | 0.81 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 1955-10-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1950)/1.73 sq M | 84 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1955-10-30 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 7-35 U/L | Normal | S |
| 1955-10-30 | ECOG Performance Status score | 1 | {score} | S | ||
| 1955-10-30 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 1955-10-08 | Leukocytes [#/volume] in Blood by Automated count | 0.7 | 10*3/uL | 4-11 10*3/uL | Low | S |
| 1955-10-08 | Neutrophils [#/volume] in Blood by Automated count | 0.1 | 10*3/uL | 1.5-7.5 10*3/uL | Low | S |
| 1955-10-08 | Hemoglobin [Mass/volume] in Blood | 7.4 | g/dL | 12-15.5 g/dL | Low | S |
| 1955-10-08 | Platelets [#/volume] in Blood by Automated count | 9 | 10*3/uL | 150-400 10*3/uL | Low | S |
| 1955-10-08 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 1955-10-08 | Potassium [Moles/volume] in Serum or Plasma | 3.3 | mmol/L | 3.5-5.1 mmol/L | Low | S |
| 1955-10-08 | Creatinine [Mass/volume] in Serum or Plasma | 0.84 | mg/dL | 0.57-1 mg/dL | Normal | S |
| 1955-10-08 | Magnesium [Mass/volume] in Serum or Plasma | 1.8 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 1955-10-08 | Q-T interval corrected | 446 | ms | Above 460 ms is prolonged in women | Normal | S |
| 1955-10-26 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 1955-10-26 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 5 | {score} | S | ||
| 1955-10-26 | Total score [AUDIT-C] | 1 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1955-09-14 | Body height | 163 | cm | S |
| 1955-09-14 | Body weight | 54 | kg | S |
| 1955-09-14 | Body mass index (BMI) [Ratio] | 20.3 | kg/m2 | S |
| 1955-09-14 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1955-09-14 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1955-09-14 | Heart rate | 96 | /min | S |
| 1955-09-14 | Respiratory rate | 16 | /min | S |
| 1955-09-14 | Body temperature | 37.2 | Cel | S |
| 1955-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1955-09-16 | Body height | 163 | cm | S |
| 1955-09-16 | Body weight | 53.8 | kg | S |
| 1955-09-16 | Body mass index (BMI) [Ratio] | 20.2 | kg/m2 | S |
| 1955-09-16 | Systolic blood pressure | 114 | mm[Hg] | S |
| 1955-09-16 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1955-09-16 | Heart rate | 100 | /min | S |
| 1955-09-16 | Respiratory rate | 18 | /min | S |
| 1955-09-16 | Body temperature | 37.3 | Cel | S |
| 1955-09-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1955-09-28 | Body height | 163 | cm | S |
| 1955-09-28 | Body weight | 53.5 | kg | S |
| 1955-09-28 | Body mass index (BMI) [Ratio] | 20.1 | kg/m2 | S |
| 1955-09-28 | Systolic blood pressure | 116 | mm[Hg] | S |
| 1955-09-28 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1955-09-28 | Heart rate | 92 | /min | S |
| 1955-09-28 | Respiratory rate | 16 | /min | S |
| 1955-09-28 | Body temperature | 36.9 | Cel | S |
| 1955-09-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1955-10-19 | Body height | 163 | cm | S |
| 1955-10-19 | Body weight | 52.8 | kg | S |
| 1955-10-19 | Body mass index (BMI) [Ratio] | 19.9 | kg/m2 | S |
| 1955-10-19 | Systolic blood pressure | 110 | mm[Hg] | S |
| 1955-10-19 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 1955-10-19 | Heart rate | 90 | /min | S |
| 1955-10-19 | Respiratory rate | 16 | /min | S |
| 1955-10-19 | Body temperature | 37 | Cel | S |
| 1955-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1955-10-30 | Body height | 163 | cm | S |
| 1955-10-30 | Body weight | 53.6 | kg | S |
| 1955-10-30 | Body mass index (BMI) [Ratio] | 20.2 | kg/m2 | S |
| 1955-10-30 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1955-10-30 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1955-10-30 | Heart rate | 84 | /min | S |
| 1955-10-30 | Respiratory rate | 16 | /min | S |
| 1955-10-30 | Body temperature | 36.8 | Cel | S |
| 1955-10-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1955-10-08 | Body height | 163 | cm | S |
| 1955-10-08 | Body weight | 52.4 | kg | S |
| 1955-10-08 | Body mass index (BMI) [Ratio] | 19.7 | kg/m2 | S |
| 1955-10-08 | Systolic blood pressure | 106 | mm[Hg] | S |
| 1955-10-08 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 1955-10-08 | Heart rate | 98 | /min | S |
| 1955-10-08 | Respiratory rate | 16 | /min | S |
| 1955-10-08 | Body temperature | 37.2 | Cel | S |
| 1955-10-08 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1955-10-26 | Body height | 163 | cm | S |
| 1955-10-26 | Body weight | 53.2 | kg | S |
| 1955-10-26 | Body mass index (BMI) [Ratio] | 20 | kg/m2 | S |
| 1955-10-26 | Systolic blood pressure | 116 | mm[Hg] | S |
| 1955-10-26 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1955-10-26 | Heart rate | 86 | /min | S |
| 1955-10-26 | Respiratory rate | 16 | /min | S |
| 1955-10-26 | Body temperature | 36.8 | Cel | S |
| 1955-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1955-09-14 | New patient visit for two months of tiredness, bruising and bleeding gums: blood count with blasts on the smear, and urgent hematology referral | finished | S |
| 1955-09-16 | Hematology consultation and bone marrow biopsy: diagnosis of acute myeloid leukemia, transfusion, and pre-treatment work-up | finished | S |
| 1955-09-28 | Genetic results, classification and risk, fitness for treatment, early palliative care, and day 1 of azacitidine with venetoclax | finished | S |
| 1955-10-19 | Day 22 of cycle 1: bone marrow response, transfusion and infection review, and stopping venetoclax for count recovery | finished | S |
| 1955-10-30 | Count recovery and response assessment; cycle 2; transplant evaluation; occupational dose records | finished | S |
| 1955-10-08 | Same-day sick visit for nausea, vomiting and constipation during cycle 1 | finished | S |
| 1955-10-26 | Periodic adult preventive visit during AML therapy | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Urgent evaluation of pancytopenia with blasts on the smear: peripheral smear review, comprehensive metabolic panel, LDH and uric acid today; coagulation tests at the hematology visit; no aspirin or anti-inflammatory drugs; go to the emergency department at once for a temperature of 38.0 °C or more, bleeding that does not stop, or new confusion or headache | completed | GL-NCCN-AML-2026 | S |
| Urgent hematology/oncology consultation within two days for suspected acute leukemia: bone marrow biopsy, classification and treatment plan | completed | GL-NCCN-AML-2026 | S |
| Occupational health history: her work with X-rays, polonium and other sources over about four decades, and the sealed-source accident in her laboratory, documented; written request to the employer's radiation safety office for her dosimetry and bioassay records, which the employer must keep and must furnish on request | completed | GL-NRC-19-13, GL-OSHA-1910-1096 | S |
| Transfusion support: irradiated, leukoreduced products; red cells one unit at a time for hemoglobin below 7 to 8 g/dL or symptoms; platelets for a count below 10 x10^3/uL, for bleeding, or before procedures that need them | completed | GL-AABB-RBC-2023, GL-AABB-PLT-2015, GL-NCCN-AML-2026 | S |
| Pre-treatment work-up: HLA typing for a future transplant, hepatitis B, hepatitis C and HIV testing, chest X-ray because of past tuberculosis, echocardiogram, lung function tests with diffusing capacity, and a dental check | completed | GL-NCCN-AML-2026, GL-ASCO-HBV-2020 | S |
| Induction with azacitidine 75 mg/m2 on days 1 to 7 and venetoclax ramped up to 70 mg daily (the dose for use with posaconazole), in 28-day cycles; admitted for the ramp-up with tumor lysis monitoring, allopurinol and fluids; bone marrow at day 21 to 28, holding venetoclax if blasts are below 5% until counts recover; later cycles with 21 days of venetoclax | completed | GL-NCCN-AML-2026, GL-ELN-AML-2022, GL-VIALE-A-2020 | S |
| Infection prevention: posaconazole, acyclovir, and levofloxacin while neutrophils are below 0.5; a written fever plan (temperature of 38.0 °C or more: go to the emergency department for antibiotics within one hour); hand hygiene and food safety | completed | GL-NCCN-INFX-2026, GL-ASCO-IDSA-FN-2018 | S |
| Specialist palliative care alongside treatment from the first cycle: symptoms, prognosis in plain numbers, her goals and values, and advance care planning, reviewed at every visit | completed | GL-ASCO-PALL-2024, GL-NCCN-AML-2026 | S |
| Allogeneic stem cell transplant evaluation by the transplant center from the first cycle: an unrelated donor search from her HLA typing, reduced-intensity conditioning if she reaches remission, and measurable residual disease monitoring | completed | GL-NCCN-AML-2026, GL-ELN-AML-2022 | S |
| Nausea and constipation during cycle 1: ondansetron as needed after a normal QTc, with no other QT-prolonging antiemetic; polyethylene glycol and senna by mouth, no rectal medicines while neutropenic; potassium replaced; red cells and platelets given; venetoclax continued with food | completed | GL-ASCO-ANTIEMETIC-2020, GL-NCCN-AML-2026, GL-AABB-PLT-2015 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Diagnosis, classification and a treatment decision within two weeks of the first visit | 1955-09-28 | completed | Marrow two days after the first visit; genetics back and treatment started on day 14 | S |
| Complete cycle 1 without tumor lysis, invasive fungal infection, or bleeding | 1955-10-30 | completed | No tumor lysis; no fever or fungal infection; no bleeding beyond bruising; one outpatient visit for nausea | S |
| Remission on the response assessment after cycle 1 (ELN 1951 complete remission, or complete remission with partial hematologic recovery) | 1955-10-30 | completed | Day-22 marrow blasts 3%; at day 33 neutrophils 0.9 and platelets 88: complete remission with partial hematologic recovery, measurable residual disease positive | S |
| Her own goals and values recorded and her symptoms controlled with the palliative care team from the first cycle | 1955-09-28 | completed | Seen by the palliative care team on day 1; goals recorded; symptoms reviewed at every visit | S |
| Her occupational dose records obtained and the exposure history documented | 1955-10-30 | active | Records requested in writing from the employer's radiation safety office; history documented | S |